Momenta Pharmaceuticals, Inc.

Sucharita Roy

Takashi Kei Kishimoto

Mallikarjun Sundaram

David J King

James Meador, Iii

Leona E Ling

Marilyn Kehry

Anthony Manning

Ishan Capila

Nur Sibel Gunay

Daniela Beccati

Ganesh Venkataraman

Nathaniel J Washburn

Ganesh Kaundinya

Jennifer Ozug

John Schaeck

Jan Hillson

Miroslaw Lech

James Iii Meador

Mallik Sundaram

The present invention features antibodies that have high binding affinity to human neonatal Fc receptor (FcRn). These anti-FcRn antibodies are useful, e.g., to promote clearance of autoantibodies in a subject, to suppress antigen presentation in a subject, to block an immune response, e.g., block an immune complex-based activation of the immune response in a subject, and to treat immunological diseases (e.g., autoimmune diseases) in a subject.

FcRn antibodies and methods of use thereof

The present application features antibodies that bind to human neonatal Fc receptor (FcRn). These anti-FcRn antibodies are useful, e.g., to promote clearance of autoantibodies in a subject, to suppress antigen presentation in a subject, to block an immune response, e.g., block an immune complex-based activation of the immune response in a subject, and to treat immunological diseases (e.g., autoimmune diseases) in a subject. These anti-FcRn antibodies are also useful, e.g., to decrease pathogenic antibody transport across the placenta of a pregnant subject, to increase pathogenic antibody catabolism in a pregnant subject, and to treat an antibody-mediated enhancement of viral disease in a fetus or a neonate.

Polysaccharide preparations lacking substantial anticoagulant activity are provided herein. Methods of making and using such preparations are provided.

Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization

Preparations of polysaccharides lacking substantial anticoagulant activity are provided herein. Methods of making and using such preparations are provided.

Non-anticoagulant polysaccharide compositions

Described are oligosaccharides having a protecting group at two, a plurality, a majority of, or each position in the oligosaccharide which is amenable to derivatization. Collections, libraries and methods of making and using such oligosaccharides are also described.

Saccharide structures and methods of making and using such structures

Methods of evaluating heparin preparations, e.g., for suitability for use as a drug or for use in making a drug, by determining the absence, presence or amount of a structural signature, wherein, e.g., the structural signature is indicative of the methods used to make the heparin preparation.

Evaluating heparin preparations

Methods of evaluating heparin preparations, e.g., for suitability for use as a drug or for use in making a drug, by determining the absence, presence or amount of a structural signature that is indicative of the methods used to make the heparin preparation.

Growing community of inventors

Tyngsboro, MA, United States of America

Sucharita Roy